RxDoctor Payments Data

Melinda Claypool

Psychiatric/Mental Health · Peoria, AZNPI 1346679768

Payments from drug & device makers

$1,156in general payments, 2019–2025

Across 58 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$259
  • AbbVie$243
  • Neurocrine Biosciences, Inc.$204
  • Alkermes, Inc.$176
  • Vanda Pharmaceuticals Inc.$93
  • Johnson & Johnson$74
  • plus $107 from 3 others

What the payments were for

  • Food & beverage$1,12697%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,156 in reported general payments places this provider in the 70th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$3,846
Medicare patients
22
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil28$100,725
IngrezzaValbenazine Tosylate11$96,245
Abilify MaintenaAripiprazole24$71,428
Invega SustennaPaliperidone Palmitate17$44,375
VraylarCariprazine Hcl11$14,910
Lurasidone Hcl60$3,504
Clozapine37$3,392
Quetiapine Fumarate125$2,593
Chlorpromazine Hcl23$2,521
Lamotrigine127$2,120
Atomoxetine Hcl21$1,615
Risperidone89$1,593
Hydroxyzine Hcl58$1,589
Trazodone Hcl115$1,579
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Aristada$176$100,72528 claims
Neurocrine Biosciences, Inc.Ingrezza$204$96,24511 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$48$71,42824 claims
Johnson & JohnsonInvega Sustenna$74$44,37517 claims
AbbVieVraylar$243$14,91011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →